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Adverse eventsPerampanel (PER) is a novel noncompetitive AMPA-receptor antagonist approved in over 40 countries for treat-
ment of partial seizures. The safety and tolerability of PER have been well-documented in three double-blind,
randomized, placebo (PBO)-controlled Phase III studies and an open-label extension (OLE). This post hoc analysis
evaluated the occurrence and characteristics of the most common treatment-emergent adverse events (TEAEs)
associated with PER. Results from the Phase III studies were pooled; post hoc analyses on the double-blind
phase and up to 1 year of the OLE were performed on the four most common TEAEs for which incidence was
higher for PER than PBO. The four most common TEAEs were dizziness, somnolence, fatigue, and irritability.
For most subjects in the Phase III double-blind studies, these TEAEs were observed during 6-week titration and
were mild or moderate in severity. For severe AEs, no dose–response relationship was observed. Patients in
the PBO group during Phase III (who therefore received their ﬁrst PER treatment during OLE) experienced
these TEAEs with incidence and timing similar to that of PER-treated patients in Phase III. The ﬁrst onset of
these TEAEs occurred during the early weeks of PER conversion in the OLE. After 6 months and up to 1 year of
PER treatment, low to no incidence of the ﬁrst onset of the four TEAEs was observed. Post hoc analyses of data
from pooled Phase III studies provide greater insight into occurrence/duration of TEAEs. Phase III double-blind
and OLE data showed that dizziness, somnolence, fatigue, and irritability were themost common TEAEs reported
by patients taking PER. Additionally, these results suggest consistency between studies in patient responses to
onset of these TEAEs. Although concomitant antiepileptic drugs (AEDs)might be predicted to affect development
of TEAEs in patients taking PER, an effect was not observed in this analysis. The low incidence of TEAEs in these
studies provides additional support for long-term PER treatment.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Perampanel (PER) is approved in theUnited States for the adjunctive
treatment of partial seizures, with or without secondarily generalized
seizures, in patients 12 years of age or older with epilepsy [1]. It is ap-
proved in the European Union, in Canada (for patients 18 years of age
or older), and, to date, has been approved in more than 40 countries
worldwide [2–4]. Perampanel has a novel mechanism of action, beingd;MedDRA,Medical Dictionary
OLE, open-label extension; PBO,
erse event.
@eisai.com (H. Yang),
ail.com (D. Xing),
. This is an open access article undera selective, noncompetitive AMPA receptor antagonist. There were
three randomized, double-blind, placebo (PBO)-controlled Phase III
studies that demonstrated signiﬁcant decreases in seizure frequency
with PER at 4-, 8-, and 12-mg daily doses compared to PBO [5–7].
All antiepileptic drugs (AEDs) are associated with risk for adverse
events (AEs); thus, minimizing AEs is an important consideration in
their successful use [8,9]. The nature, distribution, and severity of
these AEs varywidely bydrug, by patient characteristics, and by interac-
tions with other drugs, among other factors [8,9].
This article describes the post hoc analyses of the occurrence and na-
ture of AEs associated with PER therapy in patients with partial seizures
observed in the double-blind phase of three Phase III studies and during
theﬁrst 52weeks of anopen-label extension (OLE). Analysis of the pooled
Phase III data focused on the frequency, severity, time to the ﬁrst onset,
and duration of the four most common treatment-emergent adversethe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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during titration and maintenance in the three Phase III studies was also
determined. Analysis of OLE data focused on the time to the ﬁrst onset
of the TEAEs over the course of up to 52 weeks of PER treatment.
2. Methods
2.1. Phase III studies
All three Phase III studies [5–7] included subjects 12 years of age or
older with refractory partial seizures despite treatment with one to
three AEDs. The use of concomitant AEDs at baseline for PER and PBO
treatment groups is summarized in Table 1. The studies were multina-
tional, multicenter, randomized, double-blind, and PBO-controlled.
They all included an initial 6-week baseline period. This was followed
by a 19-week, double-blind phase (6 weeks of titration and 13 weeks
of maintenance). In two of the three studies, subjects were randomized
in equal proportion to once daily PER 8mg, PER 12 mg, or PBO, while in
the third study, subjects were equally randomized to once daily PER
2 mg, 4 mg, or 8 mg, or PBO. After completing the double-blind phase,
subjects were eligible to immediately enter the open-label extension
study, or proceed into a 4-week follow-up period inwhich no PER treat-
ment was provided. In all three studies, regardless of patients' baseline
AEDs, PER dosing was initiated at 2 mg daily and increased at a rate of
2 mg per week during titration until the randomized target dose was
reached. If a patient experienced tolerability issues, the investigator
had the authority to reduce the dose by 2 mg, but more than a single
2-mg dose reduction was discouraged. Subsequent uptitration was per-
mitted if tolerability issues resolved [5–7].
Assessment of safety and tolerability included recording of AEs, pre-
vious and concomitantmedication use, discontinuations, clinical labora-
tory parameters, vital signs, electrocardiography studies, physical and
neurologic examinations, and administration of both photosensitivity
and withdrawal questionnaires. Treatment-emergent adverse events
were recorded for each subject at every study visit, regardless of possi-
ble relationship to the study drug [5–7].
2.2. Open-label extension
Enrollment in the OLEwas available exclusively to subjects who had
completed the double-blind phase of a Phase III study. The ongoing OLE
is comprised of three stages: (1) a 16-week, blinded conversion period;
(2) a 256-week, open-label maintenance period; and (3) a 4-week
follow-up period [10]. Data presented herein represent results from
up to the ﬁrst 52 weeks of PER treatment.Table 1
Use of concomitant antiepileptic drugs at baseline, from pooled Phase III study data.
Antiepileptic drug Placebo group
(N = 442) n (%)
Total perampanel group
(N = 1038) n (%)
Carbamazepine 143 (32.4) 348 (33.5)
Lamotrigine 125 (28.3) 333 (32.1)
Levetiracetam 125 (28.3) 310 (29.9)
Oxcarbazepine 88 (19.9) 182 (17.5)
Topiramate 90 (20.4) 204 (19.7)
Valproic acid 140 (31.7) 338 (32.6)
CYP enzyme inducing (EIAEDs) 255 (57.7) 610 (58.8)
1 AED 27 (6.1) 66 (6.4)
2 AEDs 131 (29.6) 313 (30.2)
3 AEDs 97 (21.9) 231 (22.3)
Non-EIAEDs 187 (42.3) 427 (41.1)
1 AED 33 (7.5) 80 (7.7)
2 AEDs 87 (19.7) 220 (21.2)
3 AEDs 67 (15.2) 127 (12.2)
Total
1 AED 60 (13.6) 146 (14.1)
2 AEDs 218 (49.3) 533 (51.3)
3 AEDs 164 (37.1) 358 (34.5)All subjectswhohad attained a once daily, 12-mgdose of PER during
their Phase III study remained on that dose upon entry into the OLE.
Subjects who previously received PBO or whose dose of PER was
b12 mg/day remained blinded to their Phase III dose, which was
uptitrated during the conversion period in 2-mg increments every
2 weeks to an individualized maximum tolerated dose (MTD) of
≤12 mg/day; this titration rate was half as fast as the 2-mg/week titra-
tion of the Phase III studies. Subjects remained on their MTD of PER un-
less the investigator determined that additional dose titration was
needed to address tolerability or efﬁcacy issues. Discontinuation, also
at the investigator's discretion, was automatic for subjects unable to tol-
erate a 2-mg daily dose. Concomitant AED regimens from the Phase III
studies were maintained at entry into the OLE but could be adjusted
at the investigator's discretion. Safety evaluations in the OLE were sim-
ilar to those in the Phase III studies [10].
The study subjects were divided into two groups for this post hoc
analysis: those who received PER during both the double-blind Phase
III studies and the OLE (DB-PER, includes the 19 weeks of double-blind
Phase III studies), and those who received PBO during Phase III and con-
verted to PER during the OLE (DB-PBO, starts with the 16 weeks of
conversion in the OLE). Results from the OLE are reported here as
“time to ﬁrst onset” for TEAEs, and were analyzed over a period of up
to 52 weeks of PER treatment.
2.3. Statistical methods
A TEAEwas deﬁned as an adverse event that began either on or after
the ﬁrst dose date and up to 30 days after the last dose date of study
drug, or that began before the ﬁrst dose date and increased in severity
during the treatment period. In the analysis of overall frequency, a sub-
ject who had two or more AEs with the same Medical Dictionary for
Regulatory Activities (MedDRA) preferred term was counted only
once. Adverse event frequency was also stratiﬁed by AE severity. In
the computation of duration, if AE outcome was unrecovered, recover-
ing, or unknown, the AE ending date was imputed with the last dose
date plus 30 days. The analysis on duration of AEs was limited to the
ﬁrst AE if the subject had more than one AE.
Analysis by dose levelwas based on the dose groups at the endof the
study. Four subjects who did not receive PER at the end of the study
were not shown in ﬁgures and tables due to small n values, but were in-
cluded in the total PER group. Because this was a post hoc analysis, p
values are not provided.
3. Results
Safety results from all three Phase III studies were pooled, resulting
in a safety population of 1480 study subjects (PER, n = 1038; PBO,
n = 442). Of the 1264 study subjects who completed the double-blind
Phase III studies, 1218 (96.4%) elected to enter the OLE. Of these, 380
were DB-PBO subjects, and 838 were DB-PER subjects. The safety popu-
lation for the OLE was comprised of 1186 study subjects [10].
3.1. Pooled Phase III study data
Table 2 illustrates TEAEs occurring in ≥5% of subjects in the safety
analysis set who received PER during the double-blind Phase III studies
and has been reported previously [11,12]. Very common TEAEs were
deﬁned as those occurring in ≥10% of patients in any treatment group
and included dizziness, somnolence, headache, fatigue, irritability, and
fall. Of these, the four TEAEs occurring with greater frequency in the
total PER group than in the PBO group were dizziness (28.1% vs 9.0%),
somnolence (14.5% vs 7.2%), fatigue (8.5% vs 4.8%), and irritability
(7.0% vs 2.9%). Headache, the third most very common TEAE in the
PER group, occurred with approximately the same frequency in the
PER and PBO groups (11.4% and 11.3%, respectively). As shown in
Fig. 1, severity of the four TEAEs was mild or moderate in most cases.
Table 2
Treatment-emergent adverse events occurring in ≥5% of safety population receiving perampanel by decreasing frequency, from pooled Phase III study data.
Four very common TEAEs occurring with greater frequency in the total PER group than in the PBO group were dizziness, somnolence, fatigue, and irritability (noted in bold). Post hoc
analyses of the occurrence and nature of these 4 TEAEs were evaluated.
Sources: [11,12].
MedDRA preferred termb Placebo (N = 442) n (%) Perampanela
2 mg/day (N = 180)
n (%)
4 mg/day (N = 172)
n (%)
8 mg/day (N = 431)
n (%)
12 mg/day (N = 255)
n (%)
Total (N = 1038)
n (%)
Subjects with any TEAE 294 (66.5) 111 (61.7) 111 (64.5) 350 (81.2) 227 (89.0) 799 (77.0)
Dizziness 40 (9.0) 18 (10.0) 28 (16.3) 137 (31.8) 109 (42.7) 292 (28.1)
Somnolence 32 (7.2) 22 (12.2) 16 (9.3) 67 (15.5) 45 (17.6) 150 (14.5)
Headache 50 (11.3) 16 (8.9) 19 (11.0) 49 (11.4) 34 (13.3) 118 (11.4)
Fatigue 21 (4.8) 8 (4.4) 13 (7.6) 36 (8.4) 31 (12.2) 88 (8.5)
Irritability 13 (2.9) 7 (3.9) 7 (4.1) 29 (6.7) 30 (11.8) 73 (7.0)
Nausea 20 (4.5) 4 (2.2) 5 (2.9) 25 (5.8) 20 (7.8) 54 (5.2)
Fall 15 (3.4) 2 (1.1) 3 (1.7) 22 (5.1) 26 (10.2) 53 (5.1)
A treatment-emergent adverse event (TEAE) is deﬁned as an adverse event that either begins on or after theﬁrst dose date and up to 30days after the last dose date of studydrug, or begins
before the ﬁrst dose date and increases in severity during the treatment period. A subject with two or more adverse events with the same preferred term is counted only once for that
preferred term.
a Subjects treated during the double-blind study. Dose groups are based on the actual (randomized) treatment groups.
b Medical Dictionary for Regulatory Activities (MedDRA) preferred terms are sorted in descending order of frequency in the total perampanel column.
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(0.6% vs 0.2%), fatigue (0.5% vs 0.0%), and irritability (0.4% vs 0.0%)
were low in the total PER and PBO populations, respectively. In the 6-
mg group, severe dizziness was reported by eleven subjects (13.8%),
and no subjects reported severe fatigue. In the 8-mg group, severe diz-
ziness or fatigue was reported by eight (2.1%) and two (0.5%) subjects,
respectively. Two subjects (5.4%) from the 10-mg PER group reported
severe dizziness, and one subject (2.7%) reported severe fatigue, while
no subject in the 12-mg PER group reported a severe case of dizziness
or fatigue. Severe somnolence was reported by three subjects (3.8%)Fig. 1. Occurrences of treatment-emergent adverse events of interest by severity rating, from p
these patients experienced mild dizziness and are included in the PER total. PER, perampanel.in the 6-mg group, two subjects (0.5%) in the 8-mg group, no subjects
in the 10-mg group, and one subject (0.6%) in the 12-mg group. Severe
irritability was reported by one subject (0.5%) in the 4-mg group, one
(0.3%) in the 8-mg group, and two (1.3%) in the 12-mg group, but no
subjects in the 2-mg, 6-mg, or 10-mg groups.
Forty-three subjects (4.1%) in the PER safety population dis-
continued treatment due to these four TEAEs, compared to six subjects
(1.4%) in the PBO group. Dizziness was themost common event leading
to discontinuations in the PER group (22 [2.1%]), and it occurred more
frequently with increasing PER dose, thus, exhibiting a dose response.ooled Phase III study data. †Note: There were 4 patients in the PER 0-mg/day group; 2 of
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(somnolence, 10 [1.0%]; fatigue, 7 [0.7%]; and irritability, 4 [0.4%]),
with only discontinuations due to somnolence and irritability exhibiting
a dose response with increasing PER dose. Study drug interruption or
dose reduction resulting from these four TEAEs occurred in 136
(13.1%) PER subjects and seven (1.6%) PBO subjects. The majority of
drug interruptions or dose reductions in PER subjects resulted from diz-
ziness (85 [8.2%]), whereas somnolence (30 [2.9%]), fatigue (12 [1.2%]),
and irritability (9 [0.9%]) resulted in fewer dose adjustments. For each of
the four TEAEs, more patients receiving 8 and 12 mg of PER required
drug interruption or dose reduction compared to those receiving 2 mg
and 4 mg (based on actual treatment groups).
Time to the ﬁrst onset of each of the four TEAEs for the pooled PER
and PBO groups is shown in Fig. 2. Although new onset of these TEAEs
occurred throughout the 19-week, double-blind phase, most events
emerged during the ﬁrst 6 weeks (the titration phase). This trend for
early emergence was true for both the PER and PBO groups, although
TEAE rates were higher among subjects receiving PER. Of all cases ofFig. 2. Time to the ﬁrst onset of treatment-emergent adverse events of interest in perampa
perampanel; PBO, placebo; TEAE, treatment-emergent adverse event.ﬁrst-onset dizziness in the PER group, 83.2% occurred during the titra-
tion phase, with a peak at Week 3. This phase also included 87.3% of
ﬁrst-onset somnolence, 72.7% of ﬁrst-onset fatigue, and 56.2% of ﬁrst-
onset irritability. The peaks for all three of these TEAEs occurred at
Week 1.
The duration of the ﬁrst occurrence of the four TEAEswas highly var-
iable in each PER dose group and the PBO group, ranging from 1 day to
more than 3months. For both dizziness and somnolence, theﬁrst occur-
rence had a longermedianduration in each PER group thanPBO,where-
as the ﬁrst occurrences of fatigue and irritability had median durations
that were more variable across PER groups compared to PBO (Fig. 3).
At PER doses of 12 mg, the ﬁrst occurrences of dizziness and somno-
lence had longer median durations than at all lower doses, indicative
of a dose–response relationship for the duration of the ﬁrst occurrence
of these two TEAEs. These results also show that the median duration
of the ﬁrst occurrence was shorter in the total PER population than in
the PBO group for fatigue (46 days vs 77 days) and similar in the two
treatment groups for irritability (56 days vs 61 days), but it was longernel (N = 1038) and placebo (N = 442) groups, from pooled Phase III study data. PER,
Fig. 3.Median duration of treatment-emergent adverse events of interest: Duration of the ﬁrst occurrence per group, from pooled Phase III study data. Dose groups are based on last dose.
*n = number of subjects (placebo + total perampanel). †Note: There were 2 patients in the perampanel 0-mg/day group who experienced dizziness; these patients are included in the
perampanel total. PER, perampanel.
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(43.5 days vs 25 days).3.2. Open-label extension data
Fig. 4 compares the time to the ﬁrst onset of TEAEs of interest in the
DB-PBO group with that in the DB-PER group. Throughout 52 weeks of
PER treatment, corresponding patterns of the ﬁrst onset of TEAEs were
generally consistent between the DB-PER and DB-PBO groups. For
TEAEs occurring in N1% of subjects in the ﬁrst week during titration
(dizziness, somnolence, and fatigue), the rate of the ﬁrst onset in both
DB-PER and DB-PBO groups tapered off at approximately Week 10
(4 weeks after titration). Given that the half-life of perampanel is
approximately 105 h, this corresponds to the maintenance phase
when steady-state pharmacokinetics has been achieved [1]. With
regard to irritability, the rates of the ﬁrst onset for both groups
were ≤1%, even during titration (with the exception of Week 5 in the
DB-PBO group, when the rate increased to 1.3%). In the DB-PER group,
an increase in the rate of ﬁrst-onset dizziness and somnolence was
seen at the beginning of Week 20, corresponding with the OLE conver-
sion period, in which subjects were uptitrated to their individualized
MTDs [10]. Speciﬁcally, the rate of the ﬁrst onset for dizziness at Week
19 was 0.7%, increasing to a peak of 3% at Week 23, while the somno-
lence rate was 0.4% at Week 19, increasing to a peak of 1% at Week 22.
After approximately 26 to 52 weeks of PER treatment, both the DB-
PBO and DB-PER groups had b1% of patients experiencing the ﬁrst
onset of these four events.
For the DB-PBO group, the ﬁrst occurrences of the four TEAEs during
PER treatment manifested primarily during the 16-week conversion
period: dizziness, with a peak of 7.1% at Week 3; somnolence, with a
peak of 2.6% at Week 3; fatigue, with a peak of 2.4% at Week 1; and
irritability, with a peak of 1.3% at Week 5. This observation is similar
to the results for the patients in the DB-PER group, who experienced
the most and the highest ﬁrst onset of events during their titration pe-
riod in the double-blind Phase III studies followed by an increase in
the rate of the ﬁrst onset as subjects were uptitrated to their individual-
ized MTDs in the OLE.4. Discussion
The pooling of data from the three Phase III studies allows for amore
comprehensive perspective on the onset and characteristics of TEAEs
associated with the use of PER in patients with partial seizures than
can be developed by examining the studies individually. Furthermore,
the inclusion of up to 52weeks of data from theOLE provides additional
support to the double-blind Phase III data and allows insight into the
long-term safety of PER treatment. These data reveal dizziness, somno-
lence, fatigue, and irritability to be themost common TEAEs occurring at
a rate higher than that seen with PBO. They also show that the majority
of TEAEs observed in all of these studies were mild or moderate in se-
verity and largely occurred during the titration period, with a very low
rate of AEs in the open-label phase.
Dose-group analyses performedonTEAE severity ratings andduration
of the ﬁrst occurrence provide insight into tolerability, particularly with
higher PER dose groups. The observed discontinuations due to TEAEs or
drug interruption or dose reductions in patients receiving 8-mg and 12-
mg PER (based on actual treatment groups)may help explain the slightly
higher rates of mild, moderate, or severe TEAEs in the subjects receiving
6-mg and 10-mg PER. Speciﬁcally, patients who received 6-mg and 10-
mg PER (based on last dose) were patients who were not able to stay in
their randomized 8-mg or 12-mg dose groups. It is also important to
note that these were small n values (80 and 37 patients received 6-mg
and 10-mg PER, respectively); thus, the results should be interpreted
with caution. For duration of the ﬁrst occurrence of the TEAEs of interest,
the median durations for the 6-mg and 10-mg dose groups were not no-
tably different from those of the 8-mg and 12-mg PER groups. Nonethe-
less, a majority of subjects who experienced dizziness, somnolence,
fatigue, or irritability continued the study, although some at reduced
doses. The data presented support the notion that these TEAEs are man-
ageable. In a real-world setting where the weekly or biweekly clinical
study titration schedule of PER is not followed, these numbers may be
more favorable. Given the longhalf-life of PER, a slower titration schedule,
such as that recommended for special populations, may be more appro-
priate; thus, individual dosing should be adjusted based on tolerability.
The timing of AE occurrence is another important factor to consider
in addition to dose-group analyses. The ﬁrst onset of most of the TEAEs
Fig. 4. Time to the ﬁrst onset of treatment-emergent adverse events of interest for up to 52 weeks of perampanel treatment, from pooled Phase III study and open-label extension (OLE)
data (DB-PER, N= 838; DB-PBO, N= 378). DB-PBO= patients on placebo during the double-blind (DB) phase who converted to perampanel treatment during the OLE. Blinded conver-
sion to MTD for patients in the DB-PBO group occurred duringWeeks 1–16. DB-PER= patients on PER treatment during the DB phase (shown asWeeks 1–19) and OLE (Weeks 20–52).
Titration to randomized dose for patients in theDB-PER group occurred duringWeeks 1–6, followed by 13-weekmaintenance in theDBphase, and blinded titration toMTDduringWeeks
20–36. DB, double-blind; MTD, maximum tolerated dose; OLE, open-label extension; PBO, placebo; PER, perampanel.
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within the ﬁrst 6 weeks. This early-onset pattern was similar in the
double-blind Phase III studies, in which the titration rate was 2 mg
every week to randomized dose for 6 weeks, and in the OLE, in which
the titration rate was 2mg every 2 weeks toMTD for 16weeks. In addi-
tion to titration schedules, there were differences in doses between the
double-blind Phase III and OLE studies; speciﬁcally, in the double-blind
phase, patients were randomized to lower PER doses, including 2 mg
and 4 mg, whereas in the OLE, patients entered the study on their
ﬁnal dose of PER or PBO and were uptitrated to their individualized
MTDs of PER, which were ≤12 mg per day.
The data presented here show that a greater percentage of patients
experienced a ﬁrst onset of dizziness and somnolence during Weeks
1–10 in the DB-PBO group versus the DB-PER group (Fig. 4A and B).
This could be because the DB-PBO group uptitrated toward 12 mg or
MTD, while the DB-PER group would have reached their various
assigned dose levels from 2 mg to 12 mg during this period. On the
other hand, the percentages of patients experiencing fatigue and irrita-
bility were similar in the DB-PBO and DB-PER groups (Fig. 4C and D).
Nonetheless, patients from both groups were uptitrated to their MTDs,
which likely increased the rate of the ﬁrst onset of TEAEs despite the
slower titration rate during the OLE conversion period. For patients in
the DB-PBO group, this occurred during Weeks 1 and 16. For patients
in the DB-PER group, uptitration to MTD occurred from Weeks 20 to
36, at which point patients in the DB-PBO group were maintaining
their steady MTD doses, leading to the seemingly high incidence of diz-
ziness in the DB-PER extension phase compared to DB-PBO. Despite the
opposing contributions of slower titration rate and uptitration to MTD,
results from the double-blind Phase III studies and the OLE suggest con-
sistency between studies in patient responses with regard to early-
onset AEs. Treatment with PER resulted in very low to almost no inci-
dence of the ﬁrst onset of dizziness, somnolence, fatigue, or irritability
after approximately 26 to 52 weeks of maintenance therapy. This is in
line with safety ﬁndings from the OLE study, which concluded that in
patients with partial seizures, adjunctive PER treatment at doses up to
12 mg/day had a good tolerability proﬁle [10].
Because PER is approved for use as adjunctive therapy for partial sei-
zures, other concomitantly prescribed AEDs may inﬂuence the etiology
of the TEAEs observed in these studies. Eligible patients were required
to be receiving 1–3AEDs upon study entry, and no dose adjustment, dis-
continuation, or change of concomitant AEDs was allowed during the
Phase III studies [5–7]. However, during the OLE, concomitant AEDs
were subject to adjustment, discontinuation, or change at the
investigator's discretion [10]. Concomitant AEDs used in the Phase III
studies are listed in Table 1. According to a systematic review of AEDs
published by the Agency for Healthcare Research and Quality, dizziness
is a common AE seen with treatment with carbamazepine,
oxcarbazepine, and lamotrigine, while a separate meta-analysis of
placebo-controlled AED studies observed coordination disturbance (of
which dizziness is a commonmanifestation) as an AE frequently associ-
ated with topiramate therapy [8,9]. Psychiatric AEs, such as irritability,
although widely associated with AED use, are notably more common
with topiramate, levetiracetam, and carbamazepine than with other
AEDs [8,9,13]. Somnolence has been observed as a feature of treatment
with carbamazepine, lamotrigine, and levetiracetam, while the risk for
fatigue is increased in patients taking valproic acid, lamotrigine, or car-
bamazepine [8]. Although it is not possible to precisely determine the
effect of concomitant AED use on the incidence of AEs in this analysis,
it is important to note that the use of each AED was approximately
equal in both PER and PBO groups, suggesting that the occurrence of
AEs may be attributable to PER alone.
The implications of concomitant AEDs for AE risk extend beyond
their individual AE risk proﬁles, as drug–drug interactions between
PER and other AEDs also likely play a role. For patients whose concom-
itant AED regimen includes agents that are CYP enzyme inducing
(EIAEDs), the recommended starting daily dose of PER is 4mg, whereasthe starting dose for those not receiving EIAEDs is 2 mg [1]. Reductions
in PER plasma levels range from50% to 67%when it is takenwith EIAEDs,
including carbamazepine, oxcarbazepine, or phenytoin, and a pooled
analysis of Phase III study data showed a relative reduction in the effect
of PER when it is taken along with enzyme inducers [1]. Conversely,
concomitant treatment with AEDs that are not enzyme inducing, such
as levetiracetam, valproic acid, lamotrigine, zonisamide, clobazam, or
clonazepam, showed no effect on PER clearance [1]. In the present anal-
ysis of onset and duration of AEs, patientswere not stratiﬁed by the pres-
ence or absence of EIAEDs in their AED regimen. Nevertheless, it should
be noted that EIAED use and the corresponding change in PER plasma
concentration may contribute to the onset and duration of AEs.
5. Conclusions
Dizziness, somnolence, fatigue, and irritability were the most com-
mon AEs observed in three double-blind Phase III studies and in up to
52 weeks of the OLE study of PER for the treatment of partial seizures.
These events were largely mild or moderate in severity; nonetheless,
as supported by the data presented, individual dosing should be adjust-
ed based on tolerability. Although the ﬁrst onset of most AEs occurred
during the titration period of the double-blind Phase III studies or the
conversion period of theOLE, the frequency of AE occurrencewas slight-
ly different between these two periods. Although there is a slower titra-
tion rate in the OLE conversion period compared to that in the titration
period of the double-blind Phase III studies, which represents a poten-
tial source of this divergence, dosing differences between the double-
blind studies and the OLE may also contribute. Overall, the incidence
of the ﬁrst onset of these AEs after 6 months and up to 1 year of treat-
ment, which is low to nonexistent, provides further evidence that
long-term treatment with PER is safe and well tolerated.
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